Deng Rou, Hu Yingying, Luo Jielian, Cui Xiayu, Huo Chenxing, Zhang Runze, Zhu Liang, Zhang Wen, Fang Bangjiang
Department of Emergency, Longhua Hospital, Shanghai University of Traditional, Chinese Medicine, Shanghai, 200032, China; Liuzhou Hospital of Traditional Chinese Medicine, Liuzhou, 545001, China.
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, 471000, China.
J Ethnopharmacol. 2025 Aug 5;353(Pt A):120300. doi: 10.1016/j.jep.2025.120300.
Jinhong Tang (JHT), recorded in Surgery of Traditional Chinese Medicine, is a famous modern prescription for acute abdomen. Our previous study demonstrated that JHT can improved the immune function and organ function of patients with sepsis, achieving favorable clinical outcomes. However, the basis of these effects and the underlying mechanisms remain unclear. We aimed to explore the efficacy and mechanism of JHT in reducing septic intestinal dysfunction.
Active components of JHT, identified in prior HPLC-IT/MS analyses, were used for network pharmacology, molecular docking, and molecular dynamics simulations to predict key therapeutic targets and pathways. To functionally validate these predictions, untargeted metabolomics of colonic tissues was performed followed by pathway enrichment analysis to assess metabolic alterations. A cecal ligation and puncture (CLP)-induced septic mouse model was used to evaluate the effects of JHT on intestinal dysfunction in vivo. Histological changes were assessed via hematoxylin-eosin (HE) staining, and serum inflammatory cytokines were quantified using ELISA. Gene expression of key metabolic enzymes was measured by real-time quantitative PCR (qPCR), and protein levels of signaling molecules were analyzed by Western blotting.
Network pharmacology suggested that JHT may exert therapeutic effects through the AMPK/SIRT1/NF-κB signaling pathway. Metabolomics revealed that JHT reversed sepsis-induced disruptions in glycolysis, tricarboxylic acid (TCA) cycle, and tryptophan metabolism, while regulating mitochondrial-associated energy metabolism. In vivo, JHT significantly reduced serum TNF-α, IL-6, and IL-1β levels compared to the model group. HE staining showed reduced mucosal edema, attenuated inflammatory infiltration, and preserved colonic architecture. Western blot analysis demonstrated upregulation of AMPK, phosphorylated AMPK (p-AMPK), and SIRT1, along with downregulation of p-NF-κB and pro-inflammatory cytokines. Glycolysis-related enzymes PFKFB3 and LDHA were also significantly reduced in JHT-treated animals.
JHT alleviated septic intestinal dysfunction by modulating the AMPK/SIRT1/NF-κB signaling axis, suppressing inflammatory responses, and reprogramming abnormal glycolytic metabolism. These findings supported the multi-target, multi-pathway mechanism of JHT and provided a pharmacological basis for its application in the treatment of sepsis-associated intestinal injury.
金红汤(JHT)记载于《中医外科学》,是治疗急腹症的著名现代方剂。我们之前的研究表明,JHT可改善脓毒症患者的免疫功能和器官功能,取得了良好的临床效果。然而,这些作用的基础和潜在机制仍不清楚。我们旨在探讨JHT减轻脓毒症肠道功能障碍的疗效和机制。
利用先前高效液相色谱-离子阱/质谱(HPLC-IT/MS)分析鉴定出的JHT活性成分,进行网络药理学、分子对接和分子动力学模拟,以预测关键治疗靶点和途径。为了在功能上验证这些预测,对结肠组织进行非靶向代谢组学分析,随后进行通路富集分析以评估代谢改变。采用盲肠结扎穿刺(CLP)诱导的脓毒症小鼠模型,在体内评估JHT对肠道功能障碍的影响。通过苏木精-伊红(HE)染色评估组织学变化,使用酶联免疫吸附测定(ELISA)对血清炎性细胞因子进行定量分析。通过实时定量聚合酶链反应(qPCR)检测关键代谢酶的基因表达,通过蛋白质印迹法分析信号分子的蛋白水平。
网络药理学表明,JHT可能通过AMPK/SIRT1/NF-κB信号通路发挥治疗作用。代谢组学显示,JHT可逆转脓毒症诱导的糖酵解、三羧酸(TCA)循环和色氨酸代谢紊乱,同时调节线粒体相关的能量代谢。在体内,与模型组相比,JHT显著降低了血清肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)和白细胞介素-1β(IL-1β)水平。HE染色显示黏膜水肿减轻、炎性浸润减弱且结肠结构得以保留。蛋白质印迹分析表明,AMPK、磷酸化AMPK(p-AMPK)和SIRT1上调,同时p-NF-κB和促炎细胞因子下调。在JHT治疗的动物中,糖酵解相关酶6-磷酸果糖-2-激酶/果糖-2,6-二磷酸酶3(PFKFB3)和乳酸脱氢酶A(LDHA)也显著降低。
JHT通过调节AMPK/SIRT1/NF-κB信号轴、抑制炎症反应和重新编程异常糖酵解代谢,减轻了脓毒症肠道功能障碍。这些发现支持了JHT的多靶点、多途径作用机制,并为其在治疗脓毒症相关肠道损伤中的应用提供了药理学依据。